Atlas Trials

Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

Clinical trial NCT00790192 · COMPLETED

Trial details

NCT number
NCT00790192
Sponsor
Sumitomo Pharma America, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Schizophrenia
Start date
2008-10-01
Primary completion
2010-07-01
Enrollment
488

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.